6 results about "CD1" patented technology

The present invention discloses an antibody against Clostridium difficile specific protein, a magnetic bead-antibody conjugate and its application. The monoclonal antibody is any one of monoclonal antibody CD1, monoclonal antibody CD2, monoclonal antibody CD3 and monoclonal antibody CD4. The magnetic bead-antibody conjugate is formed by conjugating a monoclonal antibody with activated carboxyl magnetic beads to obtain the magnetic bead-antibody conjugate. Based on the magnetic bead-antibody conjugate sorting method, antibody magnetic beads that couple and recognize the Clostridium difficile secreted proteins TcdA, TcdB, the highly expressed GDH on the surface of Clostridium difficile, and the LPxTG of Clostridium difficile are used to capture Clostridium difficile, achieving the purpose of rapidly isolating Clostridium difficile from fecal samples. The present invention is based on the immunomagnetic bead separation technology of antigen-antibody reaction for separation, with the characteristics of being rapid, simple, having high enrichment efficiency and strong specificity. The present invention can be used to isolate and remove Clostridium difficile in fecal microbiota transplantation, and can also be used for strain identification and sequencing.

The present invention provides a CD1 peptide epitope for treating a disease caused by an intracellular pathogen, a method for identifying such a CD1 peptide epitope, a pharmaceutical kit comprising such a CD1 peptide epitope, and a method for treating a patient for a disease caused by an intracellular pathogen or preventing such an infection on the basis of vaccination with the CD1 peptide epitope.

This invention provides a method for screening peptides that specifically target T cells, comprising providing T cells having a subset selected from CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L) The T cells are labeled with at least one of the following surface antigen markers: CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7. The T cells are then contacted with a peptide display library, and target peptides that specifically bind to the T cells are screened therefrom.

The present invention relates to the field of biotechnology, specifically to bivalent bispecific chimeric antibodies that include a heterodimer based on the membrane-proximal domains of MHC (major histocompatibility complex) or MHC-like proteins (CD1 (cluster of differentiation 1) or HFE (hemochromatosis protein)), as well as to a technique for producing said bispecific antibodies. The invention further relates to a nucleic acid encoding said bispecific antibody, an expression vector, a host cell for producing said bivalent chimeric bispecific antibody and to a method for producing said cell.

Provided is a method for screening polypeptides that specifically target T cells, comprising: providing T cells having a surface antigen marker selected from at least one of CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L), CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7; and contacting the T cells with a polypeptide display library, and screening therefrom target polypeptides that specifically bind to the T cells.

The present disclosure describes, inter alia, fusion polypeptides comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids, as well as polynucleotides and vectors expressing such fusion polypeptides, pharmaceutical compositions comprising the polypeptides or polynucleotides encoding them, host cells for their production, and methods of using such pharmaceutical compositions as vaccines or for generation of antibodies.